Capital Fund Management (CFM)’s Cytokinetics CYTK Stock Holding History

Capital Fund Management (CFM)’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-154,381	Closed	-$5.1M	–	2495
2025 Q2	$5.1M	Buy	154,381 +99,117	+179%	+$3.45M	0.01%	1121
2025 Q1	$2.22M	Buy	55,264 +14,818	+37%	+$681K	0.01%	1383
2024 Q4	$1.9M	Buy	40,446 +4,924	+14%	+$256K	﹤0.01%	1511
2024 Q3	$1.88M	Sell	35,522 -27,160	-43%	-$1.51M	0.01%	1467
2024 Q2	$3.4M	Buy	62,682 +47,079	+302%	+$2.84M	0.01%	1146
2024 Q1	$1.09M	Buy	+15,603	New	+$1.21M	﹤0.01%	1680
2017 Q2	–	Sell	-16,600	Closed	-$213K	–	1498
2017 Q1	$213K	Buy	+16,600	New	+$194K	﹤0.01%	1379

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital Fund Management (CFM)'s CYTK Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 154,381 shares — an estimated $5.1M sold.

Capital Fund Management (CFM) first reported a position in CYTK in Q1 2017 and held it in 7 quarters. The position peaked at $5.1M in Q2 2025. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

Capital Fund Management (CFM) reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 154,381 Cytokinetics shares in Q3 2025, an estimated $5.1M.
Capital Fund Management (CFM) first reported a position in Cytokinetics in Q1 2017 and held it in 7 quarters.
Capital Fund Management (CFM)'s Cytokinetics position peaked at $5.1M in Q2 2025.
380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.